Literature DB >> 20471030

Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia.

Daniel Martins-de-Souza1, Giuseppina Maccarrone, Thomas Wobrock, Inga Zerr, Philipp Gormanns, Stefan Reckow, Peter Falkai, Andrea Schmitt, Christoph W Turck.   

Abstract

Schizophrenia (SCZ) is the result of DNA alterations and environmental factors, which together lead to differential protein expression and ultimately to the development of the illness. The diagnosis is based on clinical symptoms, and the molecular background of SCZ is not completely understood. The thalamus, whose dysfunction has been associated with SCZ based in diverse lines of evidences, plays for instance a pivotal role in the central nervous system as a relay center by re-distributing auditory and visual stimuli from diverse brain regions to the cerebral cortex. We analyzed the proteome of postmortem mediodorsal thalamus (MDT) samples from 11 SCZ patients and 8 non-SCZ individuals by using quantitative shotgun-mass spectrometry and two-dimensional gel electrophoresis. Our analyses identified 551 proteins, 50 of which showed significant differential expression. The main pathways affected by the differentially expressed proteins include energy metabolism, oligodendrocyte metabolism, and cytoskeleton assembly. The potential protein biomarkers candidates myelin basic protein and myelin oligodendrocyte protein were validated by Western blot in the MDT samples and also in cerebrospinal fluid from a separate set of samples of 17 first-episode SCZ patients and 10 healthy controls. The differential expression of μ-crystallin, protein kinase C-gamma, and glial fibrillary acidic protein were confirmed in MDT. Because we found several glycolysis enzymes to be differentially expressed, we measured the levels of pyruvate and NADPH and found them to be altered in MDT. The protein changes described here corroborate the importance of myelin/oligodendrocyte and energy metabolism in SCZ and highlight new potential biomarkers candidates that may contribute to the understanding of the pathogenesis of this complex disease.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471030     DOI: 10.1016/j.jpsychires.2010.04.014

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  63 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  Association of genetic copy number variations at 11 q14.2 with brain regional volume differences in an alcohol use disorder population.

Authors:  David Boutte; Vince D Calhoun; Jiayu Chen; Amithrupa Sabbineni; Kent Hutchison; Jingyu Liu
Journal:  Alcohol       Date:  2012-06-23       Impact factor: 2.405

3.  Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia.

Authors:  Daniel Martins-de-Souza; Maria Lebar; Christoph W Turck
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-11-19       Impact factor: 5.270

Review 4.  The role of cyclase-associated protein in regulating actin filament dynamics - more than a monomer-sequestration factor.

Authors:  Shoichiro Ono
Journal:  J Cell Sci       Date:  2013-08-01       Impact factor: 5.285

Review 5.  G72 primate-specific gene: a still enigmatic element in psychiatric disorders.

Authors:  Silvia Sacchi; Giorgio Binelli; Loredano Pollegioni
Journal:  Cell Mol Life Sci       Date:  2016-02-25       Impact factor: 9.261

6.  Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-γ, Tumor Necrosis Factor-α, and Interleukin Expression: A Tumor Model of Schizophrenia.

Authors:  James S Brown
Journal:  Schizophr Bull       Date:  2016-05-11       Impact factor: 9.306

7.  Proteomics as a tool for understanding schizophrenia.

Authors:  Daniel Martins-de-Souza
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

Review 8.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

Review 9.  Maternal immune activation and abnormal brain development across CNS disorders.

Authors:  Irene Knuesel; Laurie Chicha; Markus Britschgi; Scott A Schobel; Michael Bodmer; Jessica A Hellings; Stephen Toovey; Eric P Prinssen
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 10.  Mitochondrial dysfunction in schizophrenia: an evolutionary perspective.

Authors:  Vanessa F Gonçalves; Ana C Andreazza; James L Kennedy
Journal:  Hum Genet       Date:  2014-10-14       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.